CLOs on the Move

nference

www.nference.ai

 
Powered by its artificial intelligence software platform, nferX, nference`s mission is to synthesize the exponentially growing biomedical knowledge. nferX uses state-of-the-art neural networks (shallow and deep learning models) for real-time, automated extraction of knowledge from the commercial, scientific and regulatory body of literature.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.nference.ai
  • 101 Main Street 15th floor
    Cambridge, MA USA
  • Phone: 916.44.1254

Executives

Name Title Contact Details

Similar Companies

Emisphere Technologies

Emisphere Technologies, Inc. is a Cedar Knolls, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

AspenRidge Recovery

Call (866) 409-2172 for AspenRidge Recovery Lakewood, a Lakewood CO mens and womens addiction treatment center with mental health treatment programs.

SGX Pharmaceuticals

SGX Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cychem

Cychem is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.